Mustang Bio Inc
Research Mustang Bio Inc (MBIO) on Bullrun: market cap USD 4.18M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMBIO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 4.18M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 1.07M
- Free cash flow-USD 967.00K
Valuation Snapshot
latest market cap is USD 4.18M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 1.92M | -USD 5.26M | n/a | -0.39 | USD 17.27M | USD 0 | USD 9.53M |
| FY2024 | USD 0 | -USD 15.75M | -USD 11.41M | n/a | -38.57 | USD 6.84M | USD 878.00K | -USD 3.87M |
| FY2023 | n/a | -USD 51.60M | -USD 49.54M | n/a | -299.95 | USD 6.23M | USD 2.50M | USD 123.00K |
| FY2022 | n/a | -USD 77.53M | -USD 67.78M | n/a | -10.09 | USD 75.66M | USD 29.01M | USD 46.27M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 4.18M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 7.15M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 16.21M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 622.33M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 58.75M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 225.47M | n/a | n/a | n/a |
About Mustang Bio Inc
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Mustang Bio Inc's market cap?
Mustang Bio Inc's market capitalization is USD 4.18M.
What does Mustang Bio Inc do?
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States.